The role of hematopoietic stem cell transplantation in myelodysplastic syndrome

ONCOLOGY

Volumn 19, Issue 4, 2005, Pages 533-542

  Thompson, James E ^a   Luger, Selina M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; AMINOCAPROIC ACID; ARSENIC TRIOXIDE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; ETANERCEPT; FLUDARABINE; FLUDARABINE PHOSPHATE; LENALIDOMIDE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PENTOSTATIN; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; IRON CHELATION; META ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PATIENT ASSESSMENT; PROGNOSIS; REFRACTORY ANEMIA; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VEIN OCCLUSION; WHOLE BODY RADIATION; DECISION MAKING; METHODOLOGY; MORTALITY; ONCOLOGY; RISK ASSESSMENT; TREATMENT OUTCOME;

DECISION MAKING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MEDICAL ONCOLOGY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 23844520030     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Greenberg PL: Myelodysplastic syndrome, in Hoffman R, Benz EJ Jr, Shattil SJ, et al (eds): Hematology: Basic Principles and Practice, 3rd ed, pp 1106-1129. Philadelphia, Churchill Livingstone, 2000.
2. Greenberg P, Cox C, Le Beau M, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2083, 1997.
3. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
4. Third MIC Cooperative Study Group: Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Cancer Genet Cytogenet 32:1-10, 1988.
5. Jaffe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001.
6. Germing U, Gattermann N, Strupp C, et al: Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 24:983-992, 2000.
7. Kurzrock R, Albitar M, Cortes JE, et al: Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22:1287-1292, 2004.
8. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440, 2002.
9. Deeg HJ, Gotlib J, Beckham C, et al: Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study. Leukemia 16:162-164, 2002.
10. Raza A, Meyer P, Dutt D, et al: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958-965, 2001.
11. Greenberg PL, Baer M, Bennett JM, et al: The NCCN myelodysplastic syndromes clinical practice guidelines in oncology, version 1.2005. National Comprehensive Cancer Network. Available at www.nccn.org. Accessed March 7, 2005.
12. Estey E, Thall P, Beran M, et al: Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90:2969-2977, 1997.
13. Appelbaum FR, Anderson J: Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score. Leukemia 12:S25-29, 1998.
14. Runde V, de Witte T, Arnold R, et al: Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome. Chronic leukemia working party of the European group for blood and marrow transplantation. Bone Marrow Transplant 21:255-261, 1998.
15. de Witte T, Suciu S, Verhoef G, et al: Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98:2326-2331, 2001.
16. Guardiola P, Runde V, Bacigalupo A, et al: Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99:4370-4378, 2002.
17. Sierra J, Perez WS, Rozman C, et al: Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997-2004, 2002.
18. de Witte T, Hermans J, Vossen J, et al: Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the chronic leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:620-630, 2000.
19. Anderson JE, Appelbaum FR, Schoch G, et al: Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. Biol Blood Marrow Transplant 7:163-170, 2001.
20. Deeg HJ, Storer B, Slattery JT, et al: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201-1207, 2002.
21. Deeg HJ, Shulman HM, Anderson JE, et al: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95:1188-1194, 2000.
22. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al: Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients - report of the French Society of Bone Marrow Transplantation. J Clin Oncol 18:963-971, 2000.
23. Demuynck H, Verhoef GE, Zachee P, et al: Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant 17:745-751, 1996.
24. Sutton L, Leblond V, Ribaud P, et al: Indications and timing of allogeneic bone marrow transplantation in myelodysplastic syndromes. Leuk Lymphoma 27:475-485, 1997.
25. Anderson JE, Gooley TA, Schoch G, et al: Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 89:2578-2585, 1997.
26. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low risk myelodysplasia is associated with improved outcome. Blood 104:1224-1226, 2004.
27. Castro-Malaspina H, Harris RE, Gajewski J, et al: Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943-1951, 2002.
28. Ooi J, Iseki T, Nagayama H, et al: Unrelated cord blood transplantation for adult patients with myelodysplastic syndrome-related secondary acute myeloid leukaemia. Br J Haematol 114:834-836, 2001.
29. Carella AM, Dejana A, Lerma E, et al: In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 95:127-130, 1996.
30. Demuynck H, Delforge M, Verhoef GE, et al: Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 92:351-359, 1996.
31. Ashihara E, Shimazaki C, Okamoto A, et al: Successful peripheral blood stem cell transplantation for myelodysplastic syndrome. Bone Marrow Transplant 24:1343-1345, 1999.
32. de Witte T, van Biezen A, Hermans J, et al: Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 90:3853-3857, 1997.
33. Wattel E, Solary E, Leleu X, et al: A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia 13:524-529, 1999.
34. Oosterveld M, Muus P, Suciu S, et al: Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 16:1615-1621, 2002.
35. Martino R, Caballero MD, Perez Simon JA, et al: Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100:2243-2245, 2002.
36. Martin PJ, Hansen JA, Buckner CD, et al: Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66:664-672, 1985.
37. Maraninchi D, Gluckman E, Blaise D, et al: Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2:175-178, 1987.
38. Gale RP, Horowitz MM, Ash RC, et al: Identical-twin bone marrow transplants for leukemia. Ann Intern Med 120:646-652, 1994.
39. Porter DL, Roth MS, McGarigle C, et al: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100-106, 1994.
40. Chakraverty R, Peggs K, Chopra R, et al: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071-1078, 2002.
41. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536, 1997.
42. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998.
43. Storb R, Yu C, Wagner JL, et al: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048-3054, 1997.
44. Junghanss C, Boeckh M, Carter RA, et al: Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99:1978-1985, 2002.
45. Childs R, Clave E, Contentin N, et al: Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234-3241, 1999.
46. Antin JH, Childs R, Filipovich AH, et al: Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 7:473-485, 2001.
47. Castagna L, El Weshi A, Bourhis JH, et al: Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT). Br J Haematol 103:284-285, 1998.
48. Kroger N, Schetelig J, Zabelina T, et al: A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 28:643-647, 2001.
49. Parker JE, Shafi T, Pagliuca A, et al: Allogeneic stem cell transplantation in the myelodysplastic syndromes: Interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119:144-154, 2002.
50. Bressoud A, Chapuis B, Roux E, et al: Donor lymphocyte infusion for a patient with relapsing myelodysplastic syndrome after allogeneic bone marrow transplantation. Blood 88:1902-1903, 1996.
51. Okumura H, Takamatsu H, Yoshida T: Donor leucocyte transfusions for relapse in myelodysplastic syndrome after allogeneic bone marrow transplantation. Br J Haematol 93:386-388, 1996.
52. Nagler A, Ackerstein A, Or R, et al: Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation. Exp Hematol 28:1225-1231, 2000.
53. Matthews DC: Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Leukemia 12 (suppl 1):S33-S36, 1998.
54. Roberts TF, Foss F, Schenkein D, et al: A novel preparatory regimen associated with reduced morbidity and mortality following allogeneic bone marrow transplantation. Blood 96:781a, 2000.
55. Chan GW, Foss FM, Klein AK, et al: Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant 9:753-759, 2003.
56. Rezvani K, Lalancette M, Szydlo R, et al: Nonmyeloablative stem cell transplant (NMSCT) in AML, ALL and MDS: Disappointing outcome for patients with advanced phase disease. Blood 96(11):479a, 2000.